Changes in dopamine and DOPAC following systemic administration of apomorphine and 3,4-dihydroxyphenylamino-2-imidazoline (DPI) in rats.
Rats were injected systemically with either saline, apomorphine, or one of four doses of DPI (3,4-dihydroxyphenylamino-2-imidazoline) and the levels of dopamine and DOPAC determined in the nucleus accumbens and the caudate regions. DPI reduced dopamine and DOPAC levels in the nucleus accumbens, while apomorphine did not. On the other hand, apomorphine reduced the levels of dopamine and DOPAC in the caudate but not the nucleus accumbens. DPI largely was without effect in the caudate. The results are discussed in terms of possible specificity of the two dopamine agonists in the two forebrain regions.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism*; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D002395:Catecholamines / Q000494:pharmacology*; D002421:Caudate Nucleus / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D007093:Imidazoles / Q000494:pharmacology; D048288:Imidazolines; D007700:Kinetics; D008297:Male; D009714:Nucleus Accumbens / Q000378:metabolism; D010648:Phenylacetates / Q000378:metabolism*; D051381:Rats
D002395:Catecholamines; D007093:Imidazoles; D048288:Imidazolines; D010648:Phenylacetates; D015102:3,4-Dihydroxyphenylacetic Acid; C011775:(3,4-dihydroxyphenylamino)-2-imidazoline; D001058:Apomorphine; D004298:Dopamine